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The Fate of Autologous Endometrial
Mesenchymal Stromal Cells After Application
in the Healthy Equine Uterus
B. Elisabeth Rink,1–3 Teresa Beyer,3 Hilari M. French,1 Elaine Watson,1
Christine Aurich,3 and F. Xavier Donadeu2
Because of their distinct differentiation, immunomodulatory, andmigratory capacities, endometrial mesenchymal
stromal cells (MSCs)may provide an optimum source of therapeutic cells not only in relation to the uterus but also
for regeneration of other tissues. This study reports the fate of endometrial MSCs following intrauterine appli-
cation in mares. Stromal cell fractions were isolated from endometrial biopsies taken from seven reproductively
healthymares, expanded, and fluorescence labeled in culture. Phosphate-buffered saline (PBS) orMSCs (15· 106)
were autologously infused into each uterine horn during early diestrus and subsequently tracked by fluorescence
microscopy and flow cytometry of endometrial biopsies and blood samples taken periodically after infusion. The
inflammatory response to cell infusion was monitored in endometrial cytology samples. MSCs were detected in
endometrial sections at 6, 12, and 24 h, but not later (7 or 14 days), after cell infusion. Cells were in all cases located
in the uterine lumen, never within the endometrial tissue. No fluorescence signal was detected in blood samples at
any time point after infusion. Cytology analyses showed an increase in % of polymorphonuclear neutrophils
between 1 and 3 h after uterine infusionwith eitherMSCs or PBS and a further increase by 6 h only inmares infused
with PBS. In summary, endometrial MSCs were detected in the uterine lumen for up to 24 h after infusion, but did
not migrate into the healthy endometrium. Moreover, MSCs effectively attenuated the inflammatory response to
uterine infusion. We conclude that endometrial MSCs obtained from routine uterine biopsies could provide a safe
and effective cell source for treatment of inflammatory conditions of the uterus and potentially other tissues.
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Introduction
T issue regeneration approaches based on stem cellshave been clinically used in horses for over 15 years,
primarily involving the use of mesenchymal stromal cells
(MSCs) obtained from bone marrow (BM) and adipose tissue
(AT) [1–4] to enhance recovery of tendons, ligaments [5–7],
or diseased joints [8,9]. Although not widely explored, the
therapeutic potential of MSCs in veterinary species extends
well beyond orthopedic applications, as clearly shown in the
human field [10–12].
The endometrium has recently emerged as a promising
alternative source of therapeutic MSCs. Endometrial tissue
can be easily obtained by biopsywithout the use of anesthesia,
in contrast to the relatively invasive procedures of BM aspi-
ration or liposuction more traditionally employed to obtain
MSCs; in the case of humans, menstrual blood constitutes an
even less invasive source of MSCs [13,14]. Endometrial
MSCs were first described in humans [15,16] and were later
isolated and characterized from mice [17,18] and several
domestic species [19–25]. More recently, we were the first to
identify, isolate, and successfully expand in vitro cells from
the equine endometrium that fulfill the definition of MSCs
[26]. These cells exhibit a high proliferation rate; robustly
express typical MSC markers such as CD29, CD44, CD90,
and CD105, but lack expression of the hematopoietic mark-
ers, CD34 and CD45; and differentiate into adipogenic, os-
teogenic, and chondrogenic lineages. Additionally, compared
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with BM MSCs, endometrial MSCs have a distinct ability to
undergo smooth muscle differentiation [26] and display ro-
bust immunomodulatory [27] and migratory [28] properties.
MSC infusion has been proposed for the treatment of
highly prevalent endometrial conditions in mares, including
persistent mating-induced endometritis and endometrosis, a
condition not to be confused with endometriosis in humans,
but leading to uterine gland degeneration and infertility [29–
31]. Ferris et al. showed that BM-derived MSCs infused into
the uterus 24 h before insemination were able to modulate the
uterine inflammatory response to spermatozoa in healthy
mares. In 2013, Mambelli and associates reported that AT
MSCs infused into the uterine lumen effectively migrated and
engrafted in periglandular spaces of equine endometria [30].
The group furthermore reported improvement of histological
changes associated with endometrosis after uterine infusion
and concluded that multiple mechanisms, including homing
to fibrotic periglandular and glandular spaces, and increased
epithelial cell proliferation might mediate the antiscarring
effects of AT MSCs [32]. Moreover, Falomo et al. found that
AT MSCs could infiltrate the periglandular space as well as
single glands of endometrosis-affected tissue in vitro [33].
We reasoned that because of their origin as well as dis-
tinct differentiation, immunomodulatory, and migratory
capacities, endometrial MSCs may provide an optimum
source of therapeutic cells for uterine applications. With this
in mind, the present study aimed to follow the fate of en-
dometrial MSCs (obtained from routine endometrial biop-
sies) after autologous transplantation into the healthy uterus
during diestrus, with the hypothesis that transplanted cells
would be able to effectively infiltrate the endometrium.
Additionally, we aimed to monitor the inflammatory reac-
tion of the endometrium to intrauterine cell infusion.
Materials and Methods
Experimental mares and design
The study was performed according to the Austrian ani-
mal welfare legislation and was approved by the competent
authority for animal experimentation (Austrian Federal
Ministry for Science and Research, license numbers BMWFW-
68.205/0069-WF/3b/2016 and BMWFW-68.205/0103-WF/V/
3b/2017).
A total of sevencyclingmares of theHaflinger breed, aged 4–
7 years (mean 5.3 years), belonging to the Centre of Artificial
Insemination and Embryo Transfer, Vienna, Austria, were in-
cluded in the study. The mares were housed in outdoor pad-
docks and kept in their established group. They were fed hay
twice daily and had ad libitum access to water. Mares were
checked for signs of estrus thrice a week by ultrasound exam-
ination. When in estrus, defined by a follicle >3.5 cm and pro-
nounced uterine edema, mares were checked daily to determine
the day of ovulation. A breeding soundness examination was
performed before the beginning of the study to confirm repro-
ductive health, which included a transrectal ultrasonography
examination, a bacterial swab, and staging of tissue from an
endometrial biopsy according to Kenney and Doig [34]. All
mares were free of uterine fluid and had a negative uterine
bacterial culture and a biopsy grade I to IIa.
An experimental design was used as shown in Fig. 1A
whereby MSCs were obtained from endometrial biopsies col-
lected from a total of 7 mares on day 14 after ovulation. After
expansion in culture,MSCswere infused autologously into the
uterus during the next cycle (day4 after ovulation), followedby
periodic uterine and blood sampling. In addition, four of these
mares were also used as controls in which, two estrous cycles
before the MSC infusion cycle, they received intrauterine
phosphate-buffered saline (PBS) (1mL) on day 4 after ovula-
tion, followed by the same sampling protocol used after MSC
infusion, except that a third biopsy was not collected (Fig. 1B).
Experimental procedures
Harvest and culture of MSCs. All chemicals and reagents
used for cell culture were obtained from Life Technologies
(Thermo Fisher Scientific, Waltham, MA) unless otherwise
specified, and Nunc culture plasticware was purchased
from Sigma Aldrich (St. Louis, MO).
For all intrauterine procedures, mares were restrained in
an examination stock, the tail was wrapped, and the peri-
neum and vulva were washed with disinfectant soap, rinsed
with clean water three times, and dried with paper towels.
All intrauterine procedures were performed with sterilized
equipment and the examiner wearing long, sterile obstetric
gloves to minimize the potential of uterine contamination.
Before taking biopsies, transrectal ultrasonography was
performed on each mare to confirm the presence of a corpus
luteum and absence of intrauterine fluid. Two endometrial
biopsy specimens were collected with a standard alligator-
type biopsy punch [35] and were immersed in 50mL of PBS
on ice. Biopsy specimens were immediately processed for
MSC isolation and culture, as described [26]. In short, en-
dometrial tissue was minced and incubated in dissociation
medium (phenol red-free DMEM/F-12 containing 0.1%BSA,
0.5% collagenase I, 40mg/mL deoxyribonuclease type I, and
1% penicillin/streptomycin) for 40min at 37C, rotating at
150 rpm in a laboratory shaker (Labnet, Orbit 1000) placed in
an incubation hood (Unihood 550). The resulting cell solution
was filtered through a sterile 70-mm cell strainer (Fisher
Scientific) to eliminate undigested tissue fragments. There-
after, cells were washed in culture medium (phenol red-free
DMEM/F-12 containing 10% fetal bovine serum (FBS) and
1% penicillin/streptomycin) and resuspended in Ca2+ and
Mg2+-free PBS supplemented with 0.1% FBS and 2mM
sodium citrate. Magnetic Dynabeads M-450 (Thermo Fisher
Scientific) coated with a mucin-1 (Muc-1) antibody (Santa
Cruz, Dallas, TX), according to the manufacturers’ protocol,
were utilized to remove epithelial cells. Samples were incu-
bated with beads for 40min at 4C with gentle rotation and
tilting. The unbound (Muc-1-negative) stromal cell fraction
was collected using a Dynamagnet 2 (Thermo Fisher Sci-
entific), washed, resuspended in culture medium, and cul-
tured in a humidified incubator at 37C in 5% CO2:95% air.
Culture medium was changed every 2–3 days, and MSCs
were passaged using TrypLE when 80% confluent.
Intrauterine cell infusion. After trypsinization, cells were
labeled with the Vybrant CFDA SE Cell Tracer Kit (In-
vitrogen, Thermo Fisher Scientific) as per the manufacturer’s
instructions. The viability of labeled cells was estimated with
Trypan blue before cells were resuspended in 1mL of PBS
for intrauterine infusion. The mares were prepared as de-
scribed before and a flexible disposable insemination pipette
(Minitube, Tiefenbach, Germany) was introduced into the
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vagina. The insemination pipette was inserted into the uterus
through the cervix and guided into the left uterine horn first,
assisted by transrectal palpation. Approximately 15 million
MSCs were released into the left uterine horn using a 0.5-mL
embryo transfer straw and flexible stylet normally used for
embryo transfer procedures. The pipette was slightly retracted
and subsequently placed into the right uterine horn where
another 0.5-mL straw was used to deposit 15 million MSCs.
Uterine cytology. Samples were collected using a double-
guarded cytology brush, as described [36]. Brushes were
subsequently rolled onto each of the three glass microscope
slides, allowed to dry, fixed, stained with a commercially
available Diff Quick stain LT-SYS (Labor +Technik,
Berlin, Germany), and finally mounted. Cytology smears
were later visualized and examined under a Zeiss Imager.Z2
microscope. Five fields of vision at 200-fold magnification
were examined, cells counted, and the percentage of poly-
morphonuclear neutrophils (PMNs) relative to epithelial
cells (indicated as % PMNs) was calculated using the fol-
lowing formula: % PMN ¼ PMN
epithelial cells
· 100. Inflammation
was graded as nonexistent (<5% neutrophils), mild (5%–
10% neutrophils), moderate (15%–30% neutrophils), and
severe (>30% neutrophils) according to Card [37].
Blood sampling and flow cytometry. Blood samples were
collected from the jugular vein into EDTA tubes. Samples
were diluted 1:1 in prewarmed PBS and 4mL of this solution
was underlaid with 2mL of Ficoll-Paque (GE Healthcare,
Uppsala, Sweden) and centrifuged at room temperature for
40min at 400 g with brakes switched off. Mononucleated
cells were collected from the Ficoll-Paque–medium interface,
washed, and resuspended in PBS. The dead cell stain Cytox
blue (Life technologies, Fisher Scientific) was used according
to the manufacturer’s protocol and cells were analyzed using
a BD FACS Canto II flow cytometer equipped with FACS
Diva software. A total of 2.5· 106 events were recorded and
data were analyzed with FlowJo (version 10). CFDA SE-
labeled cells were analyzed as positive controls.
Immunofluorescence. Follow-up biopsies were collected
from the base of the right uterine horn, snap-frozen imme-
diately, and later cut into 5-mm sections using a CryoStar
NX70 (Thermo Scientific) cryotome. Sections were visual-
ized under a Zeiss Imager.Z2 fluorescence microscope.
Statistical analysis
Results are shown as mean – standard error. Normal dis-
tribution of data was confirmed using the Kolmogorov–
Smirnov test and data were analyzed by two-way analysis of
variance followed by Tukey’s test using Minitab statistics
software (Minitab, Inc., State College, PA). Significance
was set at P< 0.05.
Results
From each mare, tissues from two endometrial biopsies
were digested, yielding an average of 10 million cells, which
were then processed by magnetic beading. Culture of the
resulting unbound (stromal) fraction for*2 weeks yielded a
minimum of 30 million cells, which were used for autolo-
gous application.
No accumulation of uterine fluid was detected in any
mare during the study. Mild accumulation of air was de-
tected in most mares after uterine manipulation, but this had
resolved by 24 h.
Flow cytometry analyses of MSCs in peripheral blood. No
fluorescence signal could be detected in blood samples from
either MSC- or PBS-infused mares at 6, 12, and 24 h after
application (Supplementary Fig. S1; Supplementary Data
are available online at www.liebertpub.com/scd).
Tracking of MSCs in endometrial biopsies. We began by
collecting biopsies at 24 h and 7 and 14 days after intrauterine
infusion in 5mares. Our analyses in thesemares indicated that
fluorescence-labeled MSCs could be detected in some of the
biopsies collected at 24 h, but not in those collected at 7 or
14 days. Thus, from the two additional mares subsequently
FIG. 1. Experimental design. (A) MSCs were harvested through endometrial biopsy from 7 mares on day 14 of the cycle
before intrauterine infusion and were expanded in culture and labeled with CFDA SE. MSCs were then infused autologously
into the uterus on day 4 of the cycle, followed by collection of endometrial cytology samples at 1, 3, and 6 h, blood samples
at 6, 12, and 24 h, and endometrial biopsies at 24 h and 7 and 14 days after cell infusion. (B) Control mares (n = 4) received
intrauterine PBS on day 4 of the cycle. The same follow-up sampling protocol was used as for the MSC infusion group
except that only two biopsies were collected. MSCs, mesenchymal stromal cells; PBS, phosphate-buffered saline.
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infused with MSCs, additional biopsies were taken at 6 and
12 h after infusion. Considering all mares, fluorescence-
labeled cells were detected in biopsies collected at 6 h (2/2
mares), 12 h (2/2), and 24 h (4/7, including the two mares
collected at 6 and 12 h), but not 7 or 14 days (0/7), after MSC
infusion (Fig. 2). MSCs were in all cases located exclusively
in the uterine lumen. Moreover, no fluorescence-labeled cells
were identified in biopsies collected after infusion with PBS.
However, autofluorescence was occasionally detected within
the endometrial stroma and close to endometrial glands in
sections from either group of mares (Fig. 3).
Analyses of PMNs in endometrial cytology samples. Percen-
tages of neutrophils obtained from cytobrushes are shown in
Figure 4. In both MSC- and PBS-infused mares, percentages
of PMNs increased from about 0.3% to 7.0% between 1 and
3 h after infusion, and further increased between 3 and 6 h in
PBS-infused mares only. The percentage of PMNs was lower
in MSC- than PBS-infused mares at 6 h (7.65%– 0.81% vs.
11.2%– 1.56%, P< 0.05).
Discussion
This study reports for the first time the isolation of en-
dometrial MSCs from biopsy specimens in mares as well as
the fate of these cells after intrauterine infusion. In humans,
routine endometrial biopsy and curettage can be used ef-
fectively to obtain endometrial MSCs [38–40]. In horses,
endometrial biopsies are a safe and routine diagnostic ap-
proach and can be collected repeatedly [41]. In this study,
we demonstrate that biopsy collection is a suitable method
for isolating adequate numbers of endometrial MSCs for
subsequent short-term expansion in culture to obtain suffi-
cient cell numbers for intrauterine infusion.
Although CFDA SE-labeled MSCs were detected in the
uterine lumen at all time points during the first 24 h after
infusion, no MSCs were located within the endometrium.
Furthermore, no MSCs could be traced in any of the biopsies
collected 7 and 14 days after infusion, overall suggesting that
infused endometrial MSCs do not have the capability to mi-
grate through an intact endometrium. In contrast, a previous
study found that allogeneic AT MSCs homed in the peri-
glandular area and in single glands of uteri of mares with
endometrosis [30]. Thus, pre-existing endometrial pathology
with disruption of the epithelial lining is likely to be a pre-
requisite for MSCs to penetrate the endometrial epithelium
and incorporate into periglandular spaces, a conclusion that is
consistent with previous results in vitro [33].
Our results indicate that MSCs were being cleared from
the uterus by 24 h postinfusion, likely promoted by mild
inflammation induced by cervical and uterine manipulation
after cell infusion during early diestrus. Yet, we were not
able to detect fluorescent cells in blood, consistent with the
FIG. 2. Representative images
showing localization of CFDA SE-
labeled endometrial MSCs in sec-
tions collected at (A) 6, (B) 12, and
(C) 24 h after infusion. No labeled
cells were detected in sections
collected at (D) 7 and (E) 14 days
after application. (F) Negative
control. Scale bars 200mm. Color
images available online at www
.liebertpub.com/scd
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finding that cells did not migrate through the endometrium.
If any cells were indeed able to reach circulation, they may
have cleared quickly by entrapment in the lungs, as reported
for MSCs applied systemically in other studies [42,43].
Autofluorescence results from natural light emission
across a broad excitation and emission spectra by tissue-
intrinsic components and/or as a result of tissue processing
[44,45]. We clearly detected autofluorescence around blood
vessels and from single cells within the endometrial stroma
and endometrial glands. This may easily be misinterpreted
as migration of MSCs through endometrial stroma. Instead,
upon careful examination, it was clear that a true signal from
MSCs originated from the densely packed CFDA SE tracer
in the cell cytoplasm emitting with an intensity much higher
than autofluorescence and specifically in the FITC channel.
These observations highlight the importance of accurately
identifying fluorescent-labeled cells in histological samples
in the course of MSC-tracing studies to avoid false positive
results leading to mistaken conclusions.
In mares, an inflammatory reaction occurs physiologically
in the uterus following insemination during estrus. Such a
response is important in aiding uterine clearance and nor-
mally resolves within 24–48 h [46–48]. This inflammatory
reaction involves the recruitment of PMNs, which in healthy
mares is not apparent at 2 h, but peaks at 6 h after insemi-
nation [49]. In our study, MSCs were infused at a relatively
low volume (1mL) and during early diestrus rather than es-
trus to avoid ready elimination from the uterine lumen. A
mild inflammatory reaction occurred shortly (within 3 h) after
intrauterine infusion as expected, but was clearly attenuated
by the presence of MSCs, as indicated by a lower percentage
of PMNs in MSC-infused mares at 6 h. This observation is
FIG. 3. Representative
photomicrographs showing
autofluorescence (orange ar-
rows) in endometrial sections
from MSC- and PBS-infused
mares at 6 h and 7 and/or
14 days after infusion. CFDA
SE-labeled MSCs are indi-
cated by white arrowheads.
Scale bars at the lower right
of the image are 200mm,
scale bars at the lower left of
the image are 100 mm. Color
images available online at
www.liebertpub.com/scd
FIG. 4. Representative
photomicrographs of cytol-
ogy smears collected from
mares infused with (A)
MSCs (6 h) and (B) PBS
(3 h). Scale bars (A, B)
200 mm; Ep, epithelial cells;
PMNs, polymorphonuclear
neutrophils. (C) Percentages
of PMNs at 1, 3, and 6 h after
infusion of MSCs (n = 7 ma-
res, white bars) or PBS (n = 4
mares, gray bars). Different
superscripts (a, b, and c) indi-
cate mean differences (P<
0.05).Color images available
online at www.liebertpub
.com/scd
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consistent with results from a previous study in mares, in
which allogeneic AT MSCs were infused into the uterus 24 h
before insemination [29]. In that study, MSC infusion was
associated with an increase in the anti-inflammatory cytokine
IL-1Ra and a reduction in proinflammatory IL-1, resulting in
decreased neutrophil migration into the uterine lumen in re-
sponse to insemination. The above effects are consistent with
well-described immunomodulatory properties of MSCs [50]
and highlight the potential of MSCs for treating postbreeding
endometritis in mares.
We conclude that relatively large numbers of MSCs can
be obtained after short-term expansion (2 weeks) of cells
collected from simple endometrial biopsies in mares. En-
dometrial MSCs can be safely infused autologously into the
uterus during early diestrus where they display immuno-
modulatory properties. Although MSCs can be detected in
the uterine lumen for up to 24 h after infusion, they do not
engraft into healthy endometrium. These results highlight
the significant potential of the endometrium as a novel
source of therapeutic cells for inflammatory and degenera-
tive conditions of the uterus and potentially other tissues.
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